Abstract:
An antibacterial compound is disclosed having formula (II), wherein R1 is loweralkyl or a pharmaceutically acceptable salt, ester or prodrug thereof, processes and intermediates useful in the preparation of the above compounds, as well as compositions containing the same and methods for their use.
Abstract:
A tension responsive pinch valve is made up of a combination of an elastically flexible pinch valve element and a length of flexible tubing having a section that is to be closed automatically by being distorted to the point of pinching or kinking and thus closing the lumen when the distorted section is not under longitudinal tension. The pinch valve element is associated longitudinally with the tubing section and preferably has two end portions connected by a shank portion. The end portions are attached to the tubing section at spaced-apart points longitudinally of the flexible tubing such that the length of the encompassed section is much longer than the shank portion of the pinch valve element. If the elastic yield strength of the shank portion is greater than the bend resistance of the flexible tubing, the encompassed section of the flexible tubing will be bent over to the point of occlusion when the section is not under tension but will allow the passage of fluid when longitudinal unkinking tension is applied.
Abstract:
Immunomodulatory macrocyclic compounds having formula (I) and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, as well as pharmaceutical compositions containing such compounds and therapeutic methods of their use.
Abstract:
Embodiments described herein provide a valve construction. One embodiment comprises a first valve (12) and a second valve (14). A first fluid conveying conduit (16) fluidly conveying a first fluid is fluidly connected with the first valve (12). A second fluid conveying conduit (18) fluidly conveying a second fluid is fluidly connected with the second valve. A third fluid conveying conduit (22) is fluidly connected with the first valve (12) and the second valve (14). The first valve (12) is movable between a first position where first fluid flows between the first fluid conveying conduit and the third fluid conveying conduit, and a second position where first fluid does not flow between the first fluid conveying conduit and the third fluid conveying conduit. The second valve (14) is movable between a first position where the second fluid flows between the second fluid conveying conduit and the third fluid conveying conduit, and a second position where the second fluid does not flow between the second fluid conveying conduit and the third fluid conveying conduit.
Abstract:
A method for detecting antibody to HCV in a test sample. The method includes utilizing a recombinant protein that is the expression product of mammalian cells transformed by a heterologous expression vector comprising a DNA sequence encoding an E2 truncated protein. Test kits which include this recombinant protein also are provided.
Abstract:
The present invention is directed to an in vitro aqueous composition comprising a drug, preferably tacrolimus or rapamycin, having enhanced stability. The invention utilizes a binding protein, preferably FKBP, to stabilize the drug in an aqueous matrix.
Abstract:
The present invention provides an isolated and purified polynucleotide that encodes mammalian adenosine kinase, and to an isolated and purified adenosine kinase polypeptide. Human recombinant adenosine kinase and methods of using adenosine kinase polypeptides are also provided. Methods of making recombinant adenosine kinase using those polynucleotides and host cells transformed with those polynucleotides are also provided.
Abstract:
The present invention relates to multi-purpose vials and a process of making them. The multi-purpose vials may be used in hypodermic administrations of drug or as part of a drug delivery system.
Abstract:
Process methods are described for combining compounds of mineral nutrients into chemically stable powder mixtures that notably preserve chromium in a soluble form conducive to both absorption and bioavailability. The methods include the compounds of minerals in preferred chemical forms, procedures for treatment of certain compounds to maintain solubility, appropriate sequences for combination of the compounds and other premix ingredients, and blending to provide an adequately homogeneous mixture. The methods provide premixes of minerals that support bioavailable chromium and that exhibit good stability, solubility, odor and color for addition to nutritional products. The stable chronium -III- complexes are prepared by complexing a Cr-III powder with a carboxylic acid. The nutritional powdered mixture comprises water to substantially resist formation of insoluble chronium compounds.